CA2508917A1 - Therapeutic agents - Google Patents

Therapeutic agents Download PDF

Info

Publication number
CA2508917A1
CA2508917A1 CA002508917A CA2508917A CA2508917A1 CA 2508917 A1 CA2508917 A1 CA 2508917A1 CA 002508917 A CA002508917 A CA 002508917A CA 2508917 A CA2508917 A CA 2508917A CA 2508917 A1 CA2508917 A1 CA 2508917A1
Authority
CA
Canada
Prior art keywords
alkyl
amino
carbamoyl
heterocyclyl
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002508917A
Other languages
English (en)
French (fr)
Inventor
Richard William Arthur Luke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2508917A1 publication Critical patent/CA2508917A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
CA002508917A 2002-12-24 2003-12-19 Therapeutic agents Abandoned CA2508917A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0230089.5A GB0230089D0 (en) 2002-12-24 2002-12-24 Therapeutic agents
GB0230089.5 2002-12-24
PCT/GB2003/005568 WO2004058776A1 (en) 2002-12-24 2003-12-19 Therapeutic agents

Publications (1)

Publication Number Publication Date
CA2508917A1 true CA2508917A1 (en) 2004-07-15

Family

ID=9950374

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002508917A Abandoned CA2508917A1 (en) 2002-12-24 2003-12-19 Therapeutic agents

Country Status (16)

Country Link
US (1) US20060069109A1 (cg-RX-API-DMAC7.html)
EP (1) EP1575963B1 (cg-RX-API-DMAC7.html)
JP (1) JP2006515593A (cg-RX-API-DMAC7.html)
KR (1) KR20050087852A (cg-RX-API-DMAC7.html)
CN (1) CN1751052A (cg-RX-API-DMAC7.html)
AT (1) ATE394403T1 (cg-RX-API-DMAC7.html)
AU (1) AU2003295135A1 (cg-RX-API-DMAC7.html)
BR (1) BR0317708A (cg-RX-API-DMAC7.html)
CA (1) CA2508917A1 (cg-RX-API-DMAC7.html)
DE (1) DE60320849D1 (cg-RX-API-DMAC7.html)
ES (1) ES2305548T3 (cg-RX-API-DMAC7.html)
GB (1) GB0230089D0 (cg-RX-API-DMAC7.html)
MX (1) MXPA05006921A (cg-RX-API-DMAC7.html)
NO (1) NO20052989L (cg-RX-API-DMAC7.html)
WO (1) WO2004058776A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200504827B (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12691108B2 (en) 2019-08-12 2026-07-28 Deciphera Pharmaceuticals, Llc Methods for treating vascular malformations

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776869B2 (en) 2004-10-18 2010-08-17 Amgen Inc. Heteroaryl-substituted alkyne compounds and method of use
GB0502418D0 (en) * 2005-02-05 2005-03-16 Astrazeneca Ab Compounds
AU2015210454B2 (en) * 2005-12-23 2016-10-27 Takeda Pharmaceuticals U.S.A., Inc. Bicyclic heteroaryl compounds
DK2495016T3 (da) * 2005-12-23 2019-12-16 Ariad Pharma Inc Bicykliske heteroarylforbindelser
CN101389338B (zh) * 2005-12-23 2013-06-26 阿里亚德医药股份有限公司 双环杂芳基化合物
MX2008014290A (es) 2006-05-08 2008-11-26 Ariad Pharma Inc Compuestos heteroarilicos monociclicos.
BRPI0710328A2 (pt) 2006-05-08 2011-08-09 Ariad Pharma Inc composto da fórmula i, um tautomer da mesma, ou um sal farmaceuticamente aceitável, hidrato ou outro solvato do mesmo e método para o tratamento de cáncer em um mamìfero necessitado do mesmo e composição
JP5622393B2 (ja) 2006-12-15 2014-11-12 アブラクシスバイオサイエンス リミテッド ライアビリティー カンパニー トリアジン誘導体類及びそれらの治療応用
WO2009158432A2 (en) 2008-06-27 2009-12-30 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
JP5590040B2 (ja) 2008-11-12 2014-09-17 アリアド・ファーマシューティカルズ・インコーポレイテッド キナーゼ阻害剤としてのピラジノピラジンおよび誘導体
CA2765030C (en) 2009-06-09 2015-10-27 California Capital Equity, Llc Triazine derivatives and their therapeutical applications
EP2440053A4 (en) 2009-06-09 2012-10-31 California Capital Equity Llc BENZYL SUBSTITUTED TRIAZINE DERIVATIVES AND THERAPEUTIC APPLICATIONS THEREOF
EP2308866A1 (de) 2009-10-09 2011-04-13 Bayer CropScience AG Phenylpyri(mi)dinylpyrazole und ihre Verwendung als Fungizide
EP2508511A1 (en) * 2011-04-07 2012-10-10 Laboratoire Biodim Inhibitors of viral replication, their process of preparation and their therapeutical uses
CN104363908B (zh) * 2012-05-30 2017-12-22 霍夫曼-拉罗奇有限公司 吡咯烷基杂环类
CA2815506C (en) 2012-12-12 2018-12-11 Ariad Pharmaceuticals, Inc. Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride
US12570660B2 (en) * 2019-08-16 2026-03-10 Cyclacel Pharmaceuticals, Inc Process for the preparation of a pyrimidino-diazepine derivative

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020088406A (ko) * 1999-09-17 2002-11-27 애보트 게엠베하 운트 콤파니 카게 치료제로서의 피라졸로피리미딘
CA2395564A1 (en) * 1999-11-22 2001-05-31 Smithkline Beecham Plc Novel compounds
ES2289004T3 (es) * 2000-11-20 2008-02-01 Smithkline Beecham Corporation Nuevos compuestos.
ATE323702T1 (de) * 2002-08-06 2006-05-15 Astrazeneca Ab Kondensierte pyridine und pyrimidine mit tie2 (tek) aktivität

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12691108B2 (en) 2019-08-12 2026-07-28 Deciphera Pharmaceuticals, Llc Methods for treating vascular malformations

Also Published As

Publication number Publication date
ZA200504827B (en) 2006-04-26
US20060069109A1 (en) 2006-03-30
EP1575963B1 (en) 2008-05-07
GB0230089D0 (en) 2003-01-29
EP1575963A1 (en) 2005-09-21
AU2003295135A1 (en) 2004-07-22
KR20050087852A (ko) 2005-08-31
MXPA05006921A (es) 2005-08-18
WO2004058776A1 (en) 2004-07-15
ES2305548T3 (es) 2008-11-01
DE60320849D1 (de) 2008-06-19
JP2006515593A (ja) 2006-06-01
BR0317708A (pt) 2005-11-22
CN1751052A (zh) 2006-03-22
ATE394403T1 (de) 2008-05-15
NO20052989D0 (no) 2005-06-17
NO20052989L (no) 2005-07-21

Similar Documents

Publication Publication Date Title
EP1575963B1 (en) Anti-angiogenetic therapeutic agents
US20080027076A1 (en) Pyrimidines With Tie2 (Tek) Activity
US7427616B2 (en) Condensed pyridines and pyrimidines with tie2 (TEK) activity
US20080194552A1 (en) Aminopyrimidine Derivatives With Tie2 Inhibiting Activity
US20080153838A1 (en) Compounds Having Tie2 (Tek) Activity
KR20090053928A (ko) 증식성 질환의 치료에 유용한 모르폴리노 피리미딘 유도체
KR20090094026A (ko) Fgfr 억제제로서의 아실아미노피라졸
US20080108608A1 (en) Pyrimidines With Tie2 (Tek) Activity
US20080146599A1 (en) Pyrimidine Compounds Having Tie-2 (Tek) Inhibitory Activity
JP2008505877A (ja) ホスファチジルイノシトール(pi)3−キナーゼ阻害剤としての2,4,6−三置換ピリミジン及び癌の処置におけるその使用
ES2393215T3 (es) Derivados de morfolino pirimidina útiles en el tratamiento de trastornos proliferativos
JP2008528663A (ja) Ties(TEK)阻害活性を有するピリミジン化合物
US7476677B2 (en) Substituted thieno- and thiazolo- [2,3-d]pyrimidines and [2,3-c]pyridines as inhibitors of Tie2
ES2354457T3 (es) Compuestos de 4-(1h-indazol-5-il-amino)-quinazolina como inhibidores del receptor erbb de la tirosina quinasa para el tratamiento del cáncer.
CN101151261A (zh) 具有tie2(tek)抑制活性的嘧啶化合物
HK1102045B (en) Pyrimidines with tie2 (tek) activity

Legal Events

Date Code Title Description
FZDE Discontinued